Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) EBT Margin (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed EBT Margin for 9 consecutive years, with 780.69% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 55475.0% to 780.69% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 55.36% through Dec 2025, down 3102.0% year-over-year, with the annual reading at 343.39% for FY2025, 18133.0% down from the prior year.
  • EBT Margin for Q4 2025 was 780.69% at Marker Therapeutics, up from 162.11% in the prior quarter.
  • The five-year high for EBT Margin was 842.09% in Q4 2023, with the low at 1273.6% in Q1 2025.
  • Average EBT Margin over 4 years is 227.28%, with a median of 180.67% recorded in 2023.
  • The sharpest move saw EBT Margin soared 147685bps in 2023, then plummeted -108126bps in 2025.
  • Over 4 years, EBT Margin stood at 385.86% in 2022, then soared by 318bps to 842.09% in 2023, then crashed by -73bps to 225.94% in 2024, then surged by 246bps to 780.69% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 780.69%, 162.11%, and 479.92% for Q4 2025, Q3 2025, and Q2 2025 respectively.